Castle Biosciences CSTL Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Castle Biosciences’s reported figures.
Based on trailing twelve months.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's return on equity?
- Castle Biosciences (CSTL) reported return on equity of -2.8% in Q1 2026.
- How has Castle Biosciences's return on equity changed year-over-year?
- Castle Biosciences's return on equity decreased by 136.6% year-over-year, from -1.2% to -2.8%.
- What is the long-term trend for Castle Biosciences's return on equity?
- Over 5 years (2020 to 2025), Castle Biosciences's return on equity has grown at a 4.9% compound annual growth rate (CAGR), from -4.1% to -5.2%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.